30
Participants
Start Date
March 14, 2005
Primary Completion Date
September 14, 2017
Study Completion Date
September 14, 2017
Fludarabine
Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
Cyclophosphamide
Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
Mitoxantrone
Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
Rituximab
Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
Filgrastim
Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (2)
OSI Pharmaceuticals
INDUSTRY
Genentech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER